This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
Ocular hypertension affects over 5% of all adults; the eye does not properly drain fluid, causing eye pressure to build up
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Subscribe To Our Newsletter & Stay Updated
